Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • Leadership
    • Team
    • Publications
    • Careers
  • Diseases/Disorders
    • One Brain
    • ALS
    • Alzheimer’s
    • Autism
    • Brain Cancer
    • Brain Injury
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • Other
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
  • Ways To Give
    • Your Impact
    • How You Can Help
    • Events

Funded Grants

Back to results

Molecular characterization of transcriptional repressor capicua in GBM

Project Overview

Malignant gliomas, including oligodendrogliomas (OD) and glioblastomas (GBM), are currently incurable brain tumours with few effective treatment options. A better understanding of the molecular underpinnings of glioma is required to find new and better treatments. The goal of this study is to investigate the function of a protein that turns off gene activity called Capicua (CIC) as an important component of a cell signalling pathway that is often abnormal in cancer, called the Ras/ERK pathway. CIC is mutated in most OD tumours and lost in GBM tumours. In this project, Dr. Gelareh Zadeh and her team aim to understand how the loss of CIC contributes to malignant gliomas and to determine whether its loss impacts the efficacy of drugs that are routinely used to block the Ras/ERK pathway that have shown disappointing results in the clinic so far.

In this project, the team will examine how CIC becomes abnormally regulated, along with how the Ras/ERK pathway is activated in GBM, with the intent to discover novel targetable pathways aimed at the CIC protein’s role in cancer. Understanding these new aspects of brain cancer biology will help researchers develop new treatments for these hard to treat tumours.

Principal Investigator

Gelareh Zadeh , University Health Network, Princess Margaret, University of Toronto

Partners and Donors

Canadian Cancer Society

Project Ongoing

Molecular characterization of transcriptional repressor capicua in GBM

  • Program Type

    Team grants

  • Area of research

    Cancer

  • Disease Area

    Brain Cancer

  • Competition

    Canadian Cancer Society Innovation Grants

  • Province

    Ontario

  • Start Date

    2017

  • Total Grant Amount

    $196,000

  • Health Canada Contribution

    $98,000

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign up

© 2023 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co